Quick Answer
Tvardi Therapeutics, Inc. reported Research And Development Expense of $18.01 million for the year ending 2025.
- Tvardi Therapeutics, Inc. showed a decrease of -23.8% in Research And Development Expense from 2024 to 2025.
- This data is from Tvardi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $922.0 thousand | Q2 2013: $2.02 million | Q3 2013: $3.76 million | Q1 2014: $2.20 million | Q2 2014: $3.20 million | Q3 2014: $6.21 million | Q1 2015: $3.39 million | Q2 2015: $4.68 million | Q3 2015: $5.58 million | Q1 2016: $8.55 million | Q2 2016: $10.76 million | Q3 2016: $9.67 million | Q1 2017: $20.84 million | Q2 2017: $6.96 million | Q3 2017: $9.15 million | Q1 2018: $13.43 million | Q2 2018: $17.00 million | Q3 2018: $22.30 million | Q1 2019: $23.61 million | Q2 2019: $24.36 million | Q3 2019: $35.99 million | Q1 2020: $33.54 million | Q2 2020: $26.11 million | Q3 2020: $21.07 million | Q1 2021: $19.13 million | Q2 2021: $25.23 million | Q3 2021: $15.51 million | Q1 2022: $21.27 million | Q2 2022: $19.91 million | Q3 2022: $24.69 million | Q1 2023: $24.33 million | Q2 2023: $30.31 million | Q3 2023: $25.45 million | Q1 2024: $21.96 million | Q2 2024: $6.53 million | Q3 2024: $4.80 million | Q1 2025: $319.0 thousand | Q2 2025: $5.81 million | Q3 2025: $3.60 million.
- Over the full 14 years of available data (2012 to 2025), Tvardi Therapeutics, Inc.'s Research And Development Expense has grown by 291.8%.
- Historical annual values: Fiscal year 2025: $18.01 million | Fiscal year 2024: $23.65 million | Fiscal year 2023: $108.51 million | Fiscal year 2022: $91.88 million | Fiscal year 2021: $82.70 million | Fiscal year 2020: $107.85 million | Fiscal year 2019: $113.82 million | Fiscal year 2018: $75.53 million | Fiscal year 2017: $48.52 million | Fiscal year 2016: $49.25 million | Fiscal year 2015: $21.22 million | Fiscal year 2014: $15.07 million | Fiscal year 2013: $8.69 million | Fiscal year 2012: $4.60 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: